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Abstract
Problem: Hypertensive disorders of pregnancy continue to be on the rise in the United
States, contributing to an increase in both maternal morbidity and mortality rates. These
disorders not only have an effect on the pregnant women, but also the neonate. Early
recognition and treatment of increased blood pressure findings can improve maternal and
fetal outcomes.
Methods: This Quality Improvement (QI) project used a descriptive design and was
comprised of a retrospective chart review, focused on the effectiveness of evaluating a
hypertension bundle to improve maternal outcomes. The data collected for this project
encompassed six months pre and post bundle implementation.
Results: Charts of those patients prior to bundle implementation (n=112) and post
implementation (n=91) were reviewed for rate of hospital readmission, maternal deaths,
Intensive Care Unit (ICU) transfers, and eclampsia rates. Hospital readmissions
decreased from 4 % to 2% during post-bundle implementation even though not a
statistically significant finding with a (P=.463). A maternal death did not occur in either
pre or post bundle groups. Transfers to the ICU increased from 2% to 4% post bundle
(P=.411) and eclampsia outcomes indicated a non-significant reduction with bundle
implementation from 0% to 1% post activation (P=.448).
Implications: The use of the hypertension bundle did not improve maternal outcomes,
but the care givers did have a greater awareness of the advantages of having a
standardized practice and set of provider orders for patients who meet the hypertension
bundle criteria. Extended study time periods pre- and post-bundle implementation could
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bundle activation.
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Evaluation of a Hypertension Bundle to Improve Maternal Outcomes
Maternal morbidity and mortality have been on the rise in the United States (US)
(Kilpatrick et al., 2014). According to Callaghan, Grobman, Kilpatrick, Main, and Alton
(2014), embodied psychological and physical conditions that have an adverse effect on a
woman’s health or those aggravated by pregnancy are referred to as maternal morbidity.
On the other hand, Hoyert, Uddin and Minino (2020), describe maternal mortality as the
death of a woman during pregnancy or within 42 days of the end of a pregnancy,
irrespective of the site and duration, excluding accidental or incidental causes. In the US,
hypertensive disorders during pregnancy continue to be a leading cause of maternal
morbidity and mortality. Hypertension is a diagnosis in one in every 12 to17 pregnancies
among women ages 20 to 44 years(Centers for Disease Control [CDC], 2019). According
to Kattha and Garovic (2013), hypertensive disorders represent the most significant
complications of pregnancy and significantly contribute to both maternal and perinatal
morbidity and mortality. Hypertensive disorders cover an array of conditions including
chronic hypertension, gestational hypertension, preeclampsia/eclampsia, and
preeclampsia superimposed on chronic hypertension (The American College of
Obstetricians and Gynecologists [ACOG], 2019c; California Maternal Quality Care
Collaboration [CMQCC], 2013; Kattha & Garovic, 2013; Roberts et al., 2013).
Recognizing the risk factors and expediting treatment of hypertensive disorders with
recommended medication can assist with decreasing morbidity and mortality when the
treatment is implemented appropriately (ACOG, 2019b).
The severity of maternal hypertension has a direct correlation on maternal, fetal,
and neonatal morbidity and is considered a life-threatening obstetric emergency
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(CMQCC, 2013). Not only do these disorders affect pregnant women, but they can also
harm the neonate, leading to fetal growth restriction, preterm delivery, and perinatal
mortality. Early recognition and establishing a proper treatment regimen for hypertension
during pregnancy can assist in improving outcomes for both the pregnant women and
their neonates (Bernstein et al., 2017). Devising, implementing, and evaluating an
evidence-based bundle for the treatment of hypertension is necessary for the US to
improve maternal morbidity and mortality rates. The bundle structure offers a
standardized approach for delivering evidence-based practices to be implemented with
consistency for every patient. Hypertension bundles created should include but not be
limited to: diagnostic criteria, a specific medication regimen, both maternal and fetal
monitoring, and treatment implications.
The purpose of this project is to evaluate evidence-based care and expedite the
treatment of pregnant women who meet the hypertension bundle criteria. The project
aims to improve maternal outcomes by decreasing the progression to eclampsia,
readmissions to the hospital, transfers to the Intensive Care Unit, and maternal deaths. On
completion, the project will answer the following project question:
1. In pregnant women aged 18-45, what is the effect of instituting a maternal
hypertension bundle compared to not utilizing the bundle on the following
maternal outcomes?
a. Eclampsia
b. Readmissions within 14 days of delivery
c. Admissions to the Intensive Care Unit
d. Maternal Deaths
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Review of Literature
The literature review examined current research regarding the evaluation of
hypertension bundles used to improve maternal outcomes, along with the effects of
hypertension during pregnancy and the postpartum phase. An electronic search of the
literature was
conducted using the following databases: CINAHL, ERIC, PubMed, GOOGLE Scholar,
Science Direct along with the University of Missouri St. Louis library catalog. An initial
search of the terms “hypertension” and “pregnancy” was used and revealed over 1,000
articles. The search was then narrowed using the terms “maternal hypertension,” “ACOG
hypertension treatment,” “pregnancy outcomes with hypertension,” and “hypertension
bundle.” Search limits were used to eliminate non-English articles. Articles were chosen
based on their significance in the evaluation of hypertension and maternal outcomes. Due
to the immense volume of literature returned by the search parameters, a total of 21
articles were used in this literature review based on relevance to the study criteria.
A leading cause of maternal morbidity and mortality in the US is hypertension
and occurs in 6-8% of pregnancies in the United States (ACOG, 2019c; Bernstein et al.,
2017; Burgess & Founds, 2016; Kattah & Garovic, 2013). According to The Missouri
Pregnancy Associated Mortality Review (2020), the most common cause of death in
2017 during pregnancy was preeclampsia/eclampsia. The primary concern of having
elevated blood pressure in pregnancy relates to the potentially harmful effects on not only
the mother but the fetus (Mustafa, Ahmed, Gupta & Venuto, 2013). Both the National
High Blood Pressure Education Program of the National Heart, Lung, and Blood Institute
[NHLBI] and ACOG categorize hypertensive disorders of pregnancy into the following
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categories: chronic hypertension, gestational hypertension, preeclampsia, and
preeclampsia with superimposed preexisting hypertension (ACOG, 2019b, 2019d, 2020;
CMQCC, 2013; Mustafa et al., 2012; Roberts et al., 2013). The risk factors that
healthcare providers should note are obesity, first pregnancy, extremes in maternal age,
previous history of preeclampsia, family history of preeclampsia, a new partner, the use
of infertility treatment to become pregnant and multiple gestations (ACOG, 2019c;
Burgess & Founds, 2016; Mustafa et al., 2012; Roberts et al., 2013). Additional risk
factors include thrombophilia, kidney disease, system lupus erythematosus,
antiphospholipid antibody syndrome, obstructive sleep apnea, and those with a diagnosis
of diabetes ( ACOG, 2019b, 2019c).
According to ACOG (2019a), a systolic blood pressure (SBP) of greater than 140
or diastolic blood pressure (DBP) greater than 90 occurring prior to pregnancy or before
20 weeks’ gestation is described as chronic hypertension. It is important to note that
chronic hypertension is accompanied with both maternal morbidities associated with
severely increased blood pressure and fetal growth restriction (Roberts et al., 2013).
Gestational hypertension is a diagnosis when the SBP is 140 mm Hg or more or a DBP of
90 mm Hg or more, or both, on two separate occasions at least 4 hours apart after 20
week’s gestation, in a woman with previously normal blood pressure readings (ACOG,
2019b, 2019c; CMQCC, 2013; Mustafa et al., 2012).
Preeclampsia is a disorder of pregnancy-associated with new-onset hypertension
and proteinuria occurring after 20 weeks of gestation. In the absence of proteinuria, the
diagnosis of preeclampsia can still be made if the woman presents with any of the
following complaints in addition to hypertension; cerebral or visual disturbances,
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decreasing platelet count, pulmonary edema, and a serum elevation in creatine or liver
enzymes (ACOG, 2019c; Bernstein et al., 2017; Burgess & Founds, 2016; Burgess,
McDowell & Ebersold, 2019; CMQCC, 2013; Mustafa et al., 2012). Preeclampsia with
superimposed preexisting hypertension complicates approximately 25% of pregnancies in
women with a history of chronic hypertension and is defined as new-onset proteinuria in
a woman who has already been diagnosed with chronic high blood pressure (ACOG,
2019c; CMQCC, 2013).
The most common of these four categories of hypertensive disorders during
pregnancy is preeclampsia. Preeclampsia rates have risen nearly 25% in the past two
decades in the US (Burgess & Founds, 2016; Jeyabalan, 2013). In addition to rising
rates, the evidence is now clear that preeclampsia is associated with development of
cardiovascular disease later in life (Kattah & Garovic, 2013; Roberts et al.,2013). More
specifically, the American Heart Association guidelines (2014) for the prevention of
stroke in women, revealed that 18.2 % of women with a history of preeclampsia during
that pregnancy had a cardiovascular event within the 10 years of delivery. What is
unclear is the subsequent late-developing cardiovascular disease and the
pathophysiologic relation with a diagnosis of preeclampsia. Some researcher’s hypothesis
that preeclampsia is an inflammatory disease, associated with immune and impaired
endothelial function (Mustafa et al., 2012; Umbetov, Berdalinova, Tusupkalieyv &
Zharilkasynov, 2016).
According to Bernstein et al. (2017) and ACOG (2020), hypertension-related
complications can be significantly reduced with timely and appropriate, standardized
treatment. A multidisciplinary group of the National Partnership for Maternal Safety,
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within the Council on Patient Safety in Women’s Health Care, developed a bundle to be
utilized during pregnancy and the postpartum period in an effort to improve maternal
morbidity and mortality due to a maternal crisis involving hypertension (ACOG, 2019c;
Bernstein et al., 2017). The safety bundle can be described as a set of evidence-based
guidelines to optimally manage a woman with hypertensive disorders during her
pregnancy, thus improving the patient’s outcome. The obstetric guidelines and checklist
will facilitate both the timely recognition and treatment of hypertension (ACOG, 2020;
Bernstein et al., 2017).
The Hypertension Bundle Algorithm used as standard practice makes careful note
not to be overzealous with correcting maternal blood pressures. According to ACOG
(2019b), the action of lowering the patient’s blood pressure too quickly can cause
decreased profusion to the maternal brain and heart and to the fetus via the placenta.
Since the placenta does not autoregulate its own blood flow, the decreased perfusion to
the placenta can cause fetal heart rate abnormalities (ACOG, 2019b). Therefore, based on
evidence obtained during a systematic review of 35 randomized trials (3,573 women)
assessing different medications to be used for acute antihypertensive therapy for blood
pressures > 160/110 medications were chosen based on their therapeutic modalities
(ACOG, 2019b). The three medications added to the bundle order set are labetalol,
hydralazine, and nifedipine (AGOG 2019b, 2020; Bernstein et al., 2017; CMQCC, 2013).
Intravenous labetalol and hydralazine have been considered first-line medications for
quite some time for the management of acute-onset hypertension in both pregnant and
postpartum women (AGOC, 2019b, 2020; CMQCC, 2013). While each is effective, it is
important to note that in a meta-analysis, hydralazine was more effective than labetalol in
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lowering severe blood pressure in the pregnant patient but was associated with more
adverse maternal and perinatal effects (placental abruption, prolonged hypotension,
maternal tachycardia, oliguria, cesarean delivery, and low Apgar scores) (ACOG, 2019b;
Mustafa et al., 2012). In addition to a medication regime, the bundle also provides
guidelines for close monitoring of blood pressures as well as fetal monitoring if
applicable (ACOG, 2019c, 2020).
The hypertension bundle was developed to reduce maternal morbidity that is
associated with hypertensive disorders during pregnancy and the postpartum period.
Knowing that this disease can progress rapidly and involve multiple organ systems, it
becomes more evident that caregivers need to practice using the evidence and guidelines
provided. The obstetric hypertension checklist and guidelines assist in facilitating timely
recognition and treatment of hypertension to quickly reduce blood pressures, thus
improving maternal outcomes and reducing cerebral complications (Bernstein et al.,
2017). A common, preferred method that is used for quality improvement in healthcare is
the Plan-Do-Study-Act model (PDSA). According to Taylor et al., (2013), this
framework can provide a means for structuring the development of change and assist
with understanding the impact and benefits of the interventions to be implemented. The
improvements in outcomes are achieved by assessing what changes are needed, testing
those changes, measuring the outcomes, adjusting interventions and goals, and repeating
the cycle (Taylor et al., 2013). The PDSA cycle will be useful in evaluating the
compliance of the Hypertension Bundle.

EVALUATION OF A HYPERTENSION BUNDLE TO IMPROVE

11

Method
Design
A descriptive study design was used in this quality improvement project, utilizing
record reviews before and after the bundle was implemented. The study period prior to
the implementation covered the months of April 1, 2019, to September 30, 2019. The
months of November 1, 2019, to April 30, 2020, were used for the post-implementation
data.
Setting
An inpatient women’s service unit at a not-for-profit Catholic healthcare
organization, located in a Midwestern, suburban hospital. This facility also receives
transfers from outlying counties. In 2019, this healthcare facility delivered 8,598 babies
and had the largest Level III Neonatal Intensive Care Unit (NICU) in Missouri. This
service line employs 220 nurses, three nurse practitioners, eight nurse-midwives, 24
resident physicians, and 130 physicians as well as the Obstetric Anesthesia team. This
unit cares for any woman who has a confirmed pregnancy through the second week of the
postpartum period.
Sample
A convenience sample of 203 antepartum, intrapartum, and postpartum pregnant
patients were reviewed. Inclusion criteria included pregnant females between the ages of
18-45 who had a confirmed pregnancy, or who are no greater than two weeks postpartum,
and delivered in the hospital. The patients will have two recorded blood pressures of an
SBP > 160 or a DBP of > 110 at least 15 minutes apart. Exclusion criteria included nonpregnant females greater than two weeks postpartum, a previous diagnosis of chronic
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hypertension, pregnant females below the age of 18 and over the age of 45. Also
excluded are pregnant females who did not have at least two recorded blood pressures of
> 160/110 at least 15 minutes apart or those who delivered outside of a hospital.
Approval Process
This project was approved by the Chair of the Department, Executive Director of
Nursing, and Nurse Manager at the hospital. The Hypertension Bundle was approved for
use by the Obstetrics Specialty Committee in October 2019 and was implemented that
same month. Institutional Review Board (IRB) approval was obtained from the
University of Missouri – St. Louis (UMSL) and additionally from the hospital facility.
Additional approval was obtained from the UMSL College of Nursing Doctoral
Committee and the UMSL graduate school. There are minimal risks or ethical
considerations for this project.
Data Collection and Analysis
The Hypertension Bundle was implemented in October 2019. Data was collected
via a retrospective chart review from April 2019 to September 2019 to determine the
treatment of a patient with two recorded blood pressures of > 160/110 received before the
bundle was implemented. The following data was extracted from the medical record: the
patient’s age, gravidity, number of weeks’ gestation, blood pressure readings, notification
of the healthcare provider, medication name, time and dose(s) administered, follow-up
blood pressure, and escalation of treatment if the blood pressure remained elevated.
Additional information obtained included the number of patients that progress to having
an eclamptic seizure, readmissions to the hospital within 14 days of delivery, transfers to
the ICU, and maternal deaths. The same data was collected post implementation,
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covering the months of November 2019 to April 2020. This time frame allowed for
statistical analysis of pre-and post-intervention data (See Appendix A).
Data collection was coded and de-identified. A generated report from EPIC was
run during the months previously indicated. Charts reviewed before the implementation
of the bundle were labeled "P" before implementation or baseline beginning with P1.
Charts reviewed following the implementation of the bundle were labeled with an "A" for
after implementation, beginning with A1. All data was stored on a password-protected
computer and an encrypted USB flash drive. This information was deleted after the
completion of this project in May of 2021. Analysis of the data included descriptive
statistics to determine if there is a significant difference in patient outcomes pre- and
post- implementation of the hypertension bundle.
Procedures
A team of key stakeholders which included nursing management,
members of the Perinatal Safety Committee, Women's Service department chair, nursing
staff, obstetrician providers, obstetrician resident, and anesthesia providers was formed in
January of 2019. The team reviewed evidence from ACOG and CMQCC on the
advantages of having a standardized practice and set of provider orders for patients who
meet the hypertension bundle criteria. Prior to the implementation, the patients were
being treated with a non-standardized treatment plan and differed depending on the
provider. The stakeholders determined the unit needed to implement the hypertension
bundle to assist providers with recognizing patients who met the criteria and establish
their plan for monitoring and treating hypertensive disorders. The team agreed that the
Hypertension Bundle would was necessary and was implemented in October of 2019.
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Prior to implementing the hypertension bundle the unit nursing staff was educated
on the blood pressure parameters that would need to be reported to the provider,
frequency of patient’s blood pressures, and medications likely to be prescribed. A team
was formed to ensure the provider orders were standardized in the electronic health
record and the pharmacy was made aware so the medications could be ordered and
available. Obstetrician providers, obstetric residents and obstetric anesthesia, were
notified through email of the practice change and were provided the peer-reviewed
articles used in the decision-making process. Templates with the order set were placed on
each computer in the unit and staff were provided with a badge buddy containing the
blood pressure parameters to report as well as the additional task to perform when
implementing the hypertension bundle. Steps that were performed in order to complete
this project are:
•

successful completion of the proposal

•

defense of the proposal

•

IRB approval

•

retrospective chart review (perform initial chart search of patients who
meet inclusion criteria including two elevated blood pressures 15 minutes
apart, validation of blood pressures, notification of provider on patient’s
assessment requiring additional orders, review if antihypertension
medication was given within 60 minutes of increased reading, document
demographic data for those patients who meet bundle order initiation and
record if repeat blood pressure was performed)
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review of post-implementation charts (will be the same as above; see
Appendix A for data information tool)

The above tasks were completed, an analysis of data was performed, and the presentation
of the information was provided to the hospital facility.
Results
A total number of 203 patients’ charts (N = 203) were reviewed for this study.
There were 112 charts pre bundle activation and 91 post bundle that were reviewed. The
sample groups were found to be homogeneous, and the following demographics were
obtained. Participants in the pre-bundle group ranged in age from 19 years old to 41
years old (M = 29.5, SD = 4.7). The post-bundle group ages were 18 to 41 years old (M
= 29.7, SD = 5.6). The infants gestational age at the time of delivery pre bundle ranged
from 24 to 41 weeks (M = 35.8, SD = 3.6) and post-bundle gestational age ranged from
18-41 weeks (M = 36.5, SD = 3.6). The patient’s gravidity ranged from 1 to 8 pre-bundle
(M = 2.1, SD = 1.6) and post bundle ranged from 1 to 5 (M = 1.7, SD = 1) (see Appendix
B).
A Fisher’s exact test analysis was performed on the four variables (eclampsia,
intensive care transfers, maternal deaths, and readmissions to the hospital) both pre and
post groups to determine if there was a statistical significance between the groups.
Primary outcome results indicated a non-significant reduction in eclampsia prebundle=0% (0/112) compared to post bundle = 1% (1/91) P= .448. Transfers to the
intensive care unit resulted in 2% (2/112) pre bundle and 4% (4/91) post bundle
implementation with a P=.411. Hospital readmissions of the participants was 4% (5/112)
prior to implementation and 2% (2/91) post bundle with a P= .463. The analysis could
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not be run on the variable maternal death because no deaths occurred, and a comparison
could not be made. Thus, there were no differences pre and post bundle when referring to
maternal deaths since a maternal death did not occur (see Appendix C).
The data did satisfy two of the Pearson chi-square tests since the independent and
dependent variables are categorical and all the data is independent, but a third assumption
of chi-square test is all expected frequencies are greater than 5. Since this assumption
was violated, a Fisher’s exact test was run to account for the small group sizes to increase
the statistical power.
Discussion
This quality improvement project reviewed six months of data pre-bundle
implementation of participants with qualifying blood pressures (N=112) and six months
post-bundle participants (N=91). The p-value or significance value yielded by the
analysis was greater than .05. Therefore, there was no statistical significance noted in
maternal outcomes pre and post bundle implementation when analyzing all four variables
(eclampsia, readmissions, intensive care unit transfers, and maternal death). However,
while not statistically significant, the readmission rate is clinically significant. The
readmission rate went from 4% pre-bundle to 2% post-bundle implementation, showing a
50% reduction in post-bundle results. The Intensive Care Unit transfers was higher post
bundle implementation. This increase could be explained by possibly more critical
patients being admitted during this time due to participant condition or having a COVID19 diagnosis. Perhaps, if the study was rerun once the pandemic stabilized, we could see
a decrease in this variable.
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There are other variables that could have been considered when developing the
data tool. These variables include: was the pregnancy a multiple gestation, what was the
route of the delivery (vaginal or cesarean section), what was the pregnancy outcome (live
birth, stillborn, miscarriage), where there any complications during the pregnancy
(placenta previa, placental abruption, diabetes, etc.).
Some limitations to this study include taking into account if the patient was
receiving or received Magnesium Sulfate for the prevention of seizure activity, especially
since there was only one patient with eclampsia and that occurred with a post bundle
participant. When looking at the readmission rate, it is important to note that during the
COVID pandemic, patient length of stay was decreased and thus patients could have been
discharged prior to severe range blood pressures presenting themselves. Sample size may
limit results of this improvement project, studying a larger sample size and for a longer
time period may show improvement of maternal outcomes and statistical significance
could be identified with further analysis.
Conclusion
The study provided evidence that hospital readmissions rates were decreased post
bundle implementation even though not a statistically significant finding. The results
reveal there was no change in the number of maternal deaths pre and post bundle
implementation. That value remained at zero cases of maternal mortality. Again, there
were factors present which may have influenced the outcomes including the pandemic
and decreased length of stay which is not a common occurrence. A recommendation
would be to repeat the project using a longer time interval for the study and this could
provide a larger sample size. This larger sample size could illicit statistical significance
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in maternal outcomes as a result of implementing the hypertension bundle. Early
recognition of severe range blood pressures and notification to the obstetric provider is
essential in timely activation of the hypertension bundle. Activating the bundle offers a
standardized approach of evidence-based practices allows for consistency in care for
every patient meeting the bundle criteria.
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Figure 1. Data Collection Tool Evaluation Hypertension
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Appendix B
Figure 2. Descriptive Statistics for Age, Gestational Age, and Gravidity

Variable
Age
Gestational Age
Gravidity

Pre-Bundle
n
Min
112

M

Max
19
24
1

41
41
8

29.5
35.8
2.1

Post-Bundle
n
Min
91

SD
4.7
3.6
1.6

M

Max
18
24
1

41
41
5

29.7
36.5
1.7

SD
5.6
3.1
1.0
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Appendix C
Figure 3. Number of Patients with Examined Outcomes Pre- and Post- Bundle
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